Inspire Medical Systems Reports Preliminary Q4 And FY2024 Revenues Of $239.5M-$239.7M And $802.6M-$802.8M Versus Consensus Of 233.29M And $796.09M, Respectively

Benzinga

2025/01/13

Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business Highlights

Revenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an approximately 25% increase over the same quarter of 2023
Revenue for full year 2024 is anticipated to be in the range of $802.6 million to $802.8 million, an approximately 28% increase over full year 2023
Activated 72 new centers in the U.S. in the fourth quarter of 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy
Created 12 new sales territories in the U.S. in the fourth quarter of 2024, bringing the total to 335 U.S. sales territories
Initiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S.
Implemented a new organizational structure intended to drive continued growth

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503370082"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503370082\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503370082?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503370082","market":"us","top_or_hot":-1,"title":"Inspire Medical Systems Reports Preliminary Q4 And FY2024 Revenues Of $239.5M-$239.7M And $802.6M-$802.8M Versus Consensus Of 233.29M And $796.09M, Respectively","media":"Benzinga","content":"<html><body><p><strong>Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business Highlights</strong></p><ul><li>Revenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an approximately 25% increase over the same quarter of 2023</li><li>Revenue for full year 2024 is anticipated to be in the range of $802.6 million to $802.8 million, an approximately 28% increase over full year 2023</li><li>Activated 72 new centers in the U.S. in the fourth quarter of 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy</li><li>Created 12 new sales territories in the U.S. in the fourth quarter of 2024, bringing the total to 335 U.S. sales territories</li><li>Initiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S.</li><li>Implemented a new organizational structure intended to drive continued growth</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inspire Medical Systems Reports Preliminary Q4 And FY2024 Revenues Of $239.5M-$239.7M And $802.6M-$802.8M Versus Consensus Of 233.29M And $796.09M, Respectively</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspire Medical Systems Reports Preliminary Q4 And FY2024 Revenues Of $239.5M-$239.7M And $802.6M-$802.8M Versus Consensus Of 233.29M And $796.09M, Respectively\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-01-13 19:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business Highlights</strong></p><ul><li>Revenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an approximately 25% increase over the same quarter of 2023</li><li>Revenue for full year 2024 is anticipated to be in the range of $802.6 million to $802.8 million, an approximately 28% increase over full year 2023</li><li>Activated 72 new centers in the U.S. in the fourth quarter of 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy</li><li>Created 12 new sales territories in the U.S. in the fourth quarter of 2024, bringing the total to 335 U.S. sales territories</li><li>Initiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S.</li><li>Implemented a new organizational structure intended to drive continued growth</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSP","symbol_name":"Inspire Medical Systems","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/01/42940669/inspire-medical-systems-reports-preliminary-q4-and-fy2024-revenues-of-239-5m-239-7m-and-802-6m-802-","article_id":"2503370082","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503370082","pubTimestamp":1736769267,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business HighlightsRevenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INSP":"Inspire Medical Systems"},"translate_title":"Inspire Medical Systems报告第四季度和2024财年初步收入为2.395亿美元至2.397亿美元和8.026亿美元至8.028亿美元，而市场普遍预期分别为2.3329亿美元和7.9609亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSP":1},"content_text":"Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business HighlightsRevenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an approximately 25% increase over the same quarter of 2023Revenue for full year 2024 is anticipated to be in the range of $802.6 million to $802.8 million, an approximately 28% increase over full year 2023Activated 72 new centers in the U.S. in the fourth quarter of 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapyCreated 12 new sales territories in the U.S. in the fourth quarter of 2024, bringing the total to 335 U.S. sales territoriesInitiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S.Implemented a new organizational structure intended to drive continued growth","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}